Therapeutic options to modulate barrier defects in inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 450-454

  Hering, Nina A ^a   Schulzke, Jörg Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Barrier function; Crohn's disease; Flavonoids; Glutamine; Inflammatory bowel disease; Probiotics; Tight junction; Ulcerative colitis; Zinc

Indexed keywords

ANTIINFLAMMATORY AGENT; CLAUDIN; CLAUDIN 2; CLAUDIN 4; CLAUDIN 5; CLAUDIN 8; CYTOKINE; FLAVONOID; GAMMA INTERFERON; GLUTAMINE; INFLIXIMAB; INTERLEUKIN 13; MESALAZINE; PROBIOTIC AGENT; QUERCETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZINC;

APOPTOSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DRUG MECHANISM; ENDOCYTOSIS; ENTERITIS; HUMAN; IMMUNOCOMPETENT CELL; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE MUCOSA; INTESTINE ULCER; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TH2 CELL; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA;

EID: 70449505391     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233283     Document Type: Review

References (21)

1. Claude P: Morphological factors influencing transepithelial permeability: A model for the resistance of the zonula occludens. J Membr Biol 1978; 39: 219-232.
2. Gitter AH, Wullstein F, Fromm M, Schulzke JD: Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121: 1320-1328.
3. Schurmann G, Bruwer M, Klotz A, Schmid KW, Senninger N, Zimmer KP: Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis 1999; 14: 41-46.
4. Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH: Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor-- . Gut 2004; 53: 1817-1824.
5. Andre F, Andre C, Emery Y, Forichon J, Descos L, Minaire Y: Assessment of the lactulose- mannitol test in Crohn's disease. Gut 1988; 29: 511-515.
6. Adenis A, Colombel JF, Lecouffe P, Wallaert B, Hecquet B, Marchandise X, Cortot A: Increased pulmonary and intestinal permeability in Crohn's disease. Gut 1992; 33: 678-682.
7. Sanderson IR, Boulton P, Menzies I, Walker- Smith JA: Improvement of abnormal lactulose/ rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut 1987; 28: 1073-1076.
8. Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, Gasbarrini G: A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther 1997; 11: 735-740.
9. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor-- antibody treatment. Gut 2004; 53: 1295-1302.
10. Gennari R, Alexander JW: Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med 1997; 25: 1207-1214.
11. Li J, Langkamp-Henken B, Suzuki K, Stahlgren LH: Glutamine prevents parenteral nutrition- induced increases in intestinal permeability. JPEN J Parenter Enteral Nutr 1994; 18: 303-307.
12. Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG: Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 30: 78-84.
13. Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P: Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999; 23: 7-11.
14. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P: Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli -infected T84 cells. Infect Immun 2000; 68: 5998-6004.
15. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591.
16. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, Vecchio FM, Gasbarrini A, Gasbarrini G: Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004; 69: 225-228.
17. Planchon SM, Martins CA, Guerrant RL, Roche JK: Regulation of intestinal epithelial barrier function by TGF-- 1 . Evidence for its role in abrogating the effect of a T-cell cytokine. J Immunol 1994; 153: 5730-5739.
18. McKaig BC, Makh SS, Hawkey CJ, Podolsky DK, Mahida YR: Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF--3 . Am J Physiol 1999; 276:G1087-G1093.
19. Howe KL, Reardon C, Wang A, Nazli A, McKay DM: Transforming growth factor-- regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157: H7-induced increased permeability. Am J Pathol 2005; 167: 1587-1597.
20. Sturniolo GC, Di Leo V, Ferronato A, D'Odorico A, D'Inca R: Zinc supplementation tightens 'leaky gut' in Crohn's disease. Inflamm Bowel Dis 2001; 7: 94-98.
21. Amasheh M, Schlichter S, Amasheh S, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells. J Nutr 2008; 138: 1067-1073.